Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide vs Empagliflozin or Metformin in Newly Diagnosed T2D
NCT06083675Phase 3Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycated haemoglobin at 52 weeks. Planned start Jan 2024; status: withdrawn.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06083675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083675.